Proteomics International Laboratories (ASX:PIQ) subsidiary OxiDx's diagnostic testing technology showed a potential to identify muscle damage and recovery among athletes via a finger prick blood test, according to a Tuesday filing with the Australian bourse.
Based on a study of 20 marathon runners, the OxiDx diagnostic test was able to measure and assess exercise-induced muscle damage, the filing said.
Results were published in the Physiological Reports journal.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。